Bio-Techne Corporation (TECH)

Bio-Techne's stock has experienced notable fluctuations in the past six months. In early October 2025, the stock surged following a broader rally in healthcare stocks and reports of a potential drug-pricing agreement. In September 2025, the stock dropped after the company presented a cautious outlook at the Baird Global Healthcare Conference. Between September 30, 2024, and September 29, 2025, the share price declined. In May 2025, Bio-Techne's Board of Directors approved a stock repurchase plan, authorizing the company to repurchase $500 million in shares.

Bio-Techne's core reagents and instruments business has historically demonstrated consistent growth, driven by ongoing innovation in drug discovery and development. The company's emerging cell and gene therapy business is also projected to sustain a high growth rate. However, the company has noted challenges in the U.S. academic market and unpredictability in the biotech sector due to funding declines, which could introduce some variability in demand from these customer segments. Bio-Techne's diversified portfolio and expansion into high-growth markets aim to mitigate potential fluctuations and ensure sustained demand for its products and services.

Bio-Techne Corporation operates within the biotechnology sector, serving the pharmaceutical, biotech, academic, and diagnostic industries. The company's business is segmented into Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment focuses on biological and chemical reagents and analytical tools, accounting for approximately 75% of its revenue. The Diagnostics and Spatial Biology segment provides diagnostic products, contributing about 25% of revenue. Bio-Techne's catalog boasts over 500,000 products.

Bio-Techne maintains a significant global presence with 34 locations worldwide. Its net sales are distributed geographically, with the United States accounting for 56.7% of revenue, Europe, the Middle East, and Africa accounting for 20.8%, China accounting for 8.6%, the UK accounting for 4.3%, and Asia-Pacific accounting for 6.5%.

Bio-Techne has cultivated a strong brand reputation, recognized for its leadership in proteins, immunoassays, and clinical diagnostic controls. The company is known for its high-quality products and services, which fosters customer loyalty and supports consistent pricing. Bio-Techne's commitment to innovation is evident in its focus on proteomic analytical tools, cell and gene therapy, spatial biology, and molecular diagnostics. In September 2025, Bio-Techne released its 2025 Corporate Sustainability Report, highlighting its dedication to advancing human health and protecting the planet, which further contributes positively to its brand image.

Bio-Techne Corporation's ownership is primarily institutional, with approximately 92.29% of the company's stock held by institutional investors. Individual insiders own about 0.26% of the stock, while public companies and individual investors hold approximately 7.44%. Vanguard Group Inc is the largest individual shareholder, owning 18.44 million shares, representing 11.85% of the company.